Cargando…
Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
INTRODUCTION: The terminal complement C5 inhibitor ravulizumab has a long elimination half-life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized, placebo-controlled period (RCP) of the CHAMPION MG study, ravulizumab provided rapid and sustained efficacy and was we...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188401/ https://www.ncbi.nlm.nih.gov/pubmed/36890354 http://dx.doi.org/10.1007/s00415-023-11617-1 |